local_hospital

CERMEP - imagerie du vivant

Address
59, Boulevard Pinel, 69677 Bron, France

Analytical, Diagnostic and Therapeutic Techniques and Equipment

At CERMEP - imagerie du vivant, clinical research in this area focuses on diagnostic imaging and the evaluation of biological markers linked to Parkinson disease. The studies are designed to better understand how brain receptors and signaling systems change in people with neurological disease, supporting more precise detection and interpretation of early abnormalities.

  • Testing imaging-based approaches to measure the 5-HT4 receptor in Parkinson's disease
  • Using advanced brain imaging to explore early changes in the serotoninergic system
  • Comparing findings in patients and healthy controls to improve diagnostic insight

These trials aim to refine how neurological disorders are identified and characterized, with a particular emphasis on imaging tools that can reveal subtle disease-related changes.

Nervous System Diseases

This research site is also active in nervous system disease studies centered on Parkinson disease and its early stages. The work examines how brain chemistry is affected before and after clear symptoms appear, helping researchers learn more about disease development and progression.

  • Studying Parkinson's disease in people with mild to moderate symptoms
  • Investigating the prodromal phase of Parkinson's disease in individuals carrying SNCA gene mutations
  • Assessing whether brain imaging can detect early neurological changes linked to disease onset

The main purpose is to improve understanding of disease mechanisms and support earlier recognition of Parkinsonian disorders before they fully develop.

Pathological Conditions, Signs and Symptoms

Clinical trials at CERMEP also address pathological conditions associated with movement and brain function, focusing on symptoms and underlying changes that may appear during the course of Parkinson's disease. This line of research helps connect clinical features with measurable biological alterations.

  • Exploring symptom-related brain changes in people with Parkinson disease
  • Evaluating early abnormalities that may precede visible motor symptoms
  • Linking clinical presentation with serotonergic system impairment

These studies are intended to improve the interpretation of disease signs and support better clinical assessment of patients at different stages of illness.

Musculoskeletal and Neural Physiological Phenomena

Research in this therapeutic area examines how musculoskeletal and neural physiological processes are altered in Parkinson's disease. By observing brain system activity in both affected participants and healthy controls, the trials seek to clarify how movement-related biology shifts as the disease emerges and evolves.

  • Investigating changes in brain physiology during the prodromal stage of disease
  • Comparing neural signaling patterns between patients and control participants
  • Studying how early biological changes may relate to later motor impairment

The research is aimed at understanding the physiological pathways involved in Parkinsonian disorders and identifying changes that could support earlier intervention.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
3
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
2
Active sponsors
1

Sponsor Network

Top 1 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
2
Outperforms 44% of sites
public
Therapeutic diversity
4areas
Outperforms 69% of sites
groups
Sponsor diversity
2sponsors
Outperforms 45% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in CERMEP - imagerie du vivant

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Evaluation of Serotoninergic System Alterations in Prodromal Parkinson's Disease with SNCA Mutations Using [11C]DASB and [11C]SB207145 PET ImagingInstitut National De La Sante Et De La Recherche MedicalePhase IVNot Yet Recruiting

IMP list

lock Showing 1 of 3 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
(1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE1Unknown2023-09-182023-09-18

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.